Ethicon Endo-Surgery Completes Divestiture of Breast Care Business to Devicor Medical Products
CINCINNATI, July 12 /PRNewswire/ — Ethicon Endo-Surgery, Inc. (EES), a Johnson & Johnson company, today announced it has completed the divestiture of its Breast Care business to Devicor Medical Products, Inc., a portfolio company of GTCR. Financial terms of the transaction are not being disclosed.
Under the terms of the transaction, Devicor has acquired the entire EES Breast Care product portfolio, including the MAMMOTOME(Ã‚® )Breast Biopsy System and tissue markers (MammoMARK(Ã‚®), MicroMARK(Ã‚®), and CoreMARK(Ã‚®)) used for breast disease diagnostic sampling and management. Additionally, EES has transferred marketing and distribution rights for Neoprobe(Ã‚®) Gamma Detection Systems to Devicor. Approximately 300 employees supporting the business will transfer to Devicor, subject to local laws.
“Associates in the Breast Care business have made it what it is today: the global leader in vacuum assisted breast biopsy devices,” said Karen Licitra, Company Group Chairman, and Worldwide Franchise Chairman, Ethicon Endo-Surgery. “The MAMMOTOMEÃ‚® brand is recognized worldwide, and we believe Devicor provides a promising fit to help the Breast Care business achieve its full potential.”
About Ethicon Endo-Surgery, Inc.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, develops and markets advanced medical devices for minimally invasive and open surgical procedures, focusing on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, gynecology and surgical oncology. More information can be found at www.ethiconendo.com.
SOURCE Ethicon Endo-Surgery, Inc.